We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca and Eli Lilly have agreed to conduct a clinical trial to assess the safety and preliminary efficacy of AZ’s experimental anti-PD-L1 immune checkpoint inhibitor MEDI4736 in combination with Lilly’s Cyramza treatment for patients with advanced solid cancer tumors. Read More
A Luxembourg-based nonprofit set up by European pharma groups is one step closer to launching a counterfeit drug repository system, having finalized contracts with three software firms to help implement the system. Read More
AstraZeneca has sold global rights, excluding the U.S., to its Entocort gastroenterology drug to Tillotts Pharma for $215 million, as it focuses on cancer and diabetes therapies. Read More
Increasing data is driving collaboration among drugmakers, insurers, health systems and technology firms to deliver cost-effective and improved treatments to patients, a just-released PwC report concludes. Read More